Polyphor AG priced its IPO at CHF38 per share — the upper end of its revised price range.
The IPO price implies a total market capitalization of CHF420 million.
The company will list its shares on the SIX Swiss Exchange under the symbol POLN beginning May 15, with settlement expected around May 17.
The syndicate banks placed 4,342,110 newly issued shares with investors. The company also granted syndicate banks an option to buy up to 263,160 additional shares to cover overallotments. The total placement volume, assuming full exercise of the overallotment option, is CHF165 million.
Polyphor plans to use proceeds raised from the IPO for the development of its products murepavadin and balixafortide.
UBS AG and Deutsche Bank AG are acting as joint global coordinators and joint book runners, while Cantonal Bank of Zurich and Cantor Fitzgerald are acting as co-lead managers for the IPO.
Octavian is acting as selling agent, while Skadden Arps Slate Meagher & Flom LLP and Vischer AG are acting as legal advisers to Polyphor. Linklaters LLP and Bär & Karrer Ltd. are representing the managers.
Switzerland's Polyphor is a specialty pharmaceutical company focused on developing macrocycle drugs to address antibiotic resistance and severe respiratory diseases.